Poly-L-lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 6, 2013, Pages 703-709

  Dubois, Alice V ^a,b   Midoux, Patrick ^c   Gras, Delphine ^d   Si Tahar, Mustapha ^a,b   Bréa, Déborah ^a,b   Attucci, Sylvie ^a,b   Khelloufi, Mustapha Kamel ^d   Ramphal, Reuben ^a,b   Diot, Patrice ^a,b   Gauthier, Francis ^a,b   Herve, Virginie ^a,b  

^a Université Franaois Rabelais   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^d INSERM   (France)

Author keywords

Antibacterial agents; Cystic fibrosis; Polylysine; Protease inhibitors; Sputum

Indexed keywords

CATHEPSIN G; COLISTIN; DORNASE ALFA; LEUKOCYTE ELASTASE; PEPTIDASE; POLYLYSINE; SERINE PROTEINASE; TOBRAMYCIN;

ADULT; AEROSOL; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS EPITHELIUM; LUNG DISEASE; LUNG FUNCTION TEST; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS;

ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; CATHEPSIN G; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; DNA; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTE ELASTASE; LUNG; LYSINE; MALE; MICE; MIDDLE AGED; NEUTROPHILS; PEPTIDE HYDROLASES; PROTEOLYSIS; PSEUDOMONAS AERUGINOSA; SPUTUM; STAPHYLOCOCCUS AUREUS;

EID: 84884655341     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201305-0912OC     Document Type: Article

References (38)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
2. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007;13:231-240.
3. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol 2007;35:116-129.
4. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011;24:29-70.
5. Meluleni GJ, Grout M, Evans DJ, Pier GB. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 1995;155:2029-2038.
6. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001;9:34-39.
7. Voynow JA, Fischer BM, Zheng S. Proteases and cystic fibrosis. Int J Biochem Cell Biol 2008;40:1238-1245.
8. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010;62:726-759.
9. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest 2009;135:505-512.
10. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-1535.
11. Manzenreiter R, Kienberger F, Marcos V, Schilcher K, Krautgartner WD, Obermayer A, Huml M, Stoiber W, Hector A, Griese M, et al. Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy. J Cyst Fibros 2012;11:84-92.
12. Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Fessler MB, Malcolm KC, Vasil ML, Nick JA. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 2005;73:3693-3701.
13. Lewenza S. Extracellular DNA-induced antimicrobial peptide resistance mechanisms in Pseudomonas aeruginosa. Front Microbiol 2013;4:21.
14. Dubois AV, Gauthier A, Bréa D, Varaigne F, Diot P, Gauthier F, Attucci S. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum. Am J Respir Cell Mol Biol 2012;47:80-86.
15. Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006;29:201-207.
16. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS; Recombinant AAT CF Study Team. Safety and efficacy of recombinant alpha (1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006;41:177-183.
17. Hodson ME, Shah PL. DNase trials in cystic fibrosis. Eur Respir J 1995;8:1786-1791.
18. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Döring G, van Koningsbruggen S, et al.; Bronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-725.
19. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52:1176-1193; discussion 1193-1177.
20. Milla CE. Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax 1998;53:1014-1017.
21. Sanders NN, Franckx H, De Boeck K, Haustraete J, De Smedt SC, Demeester J. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax 2006;61:962-968.
22. Midoux P, Pichon C, Yaouanc JJ, Jaffrès PA. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009;157:166-178.
23. Montier T, Delépine P, Pichon C, Férec C, Porteous DJ, Midoux P. Nonviral vectors in cystic fibrosis gene therapy: progress and challenges. Trends Biotechnol 2004;22:586-592.
24. Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004;15:1255-1269.
25. Shima S, Matsuoka H, Iwamoto T, Sakai H. Antimicrobial action of epsilon-poly-L-lysine. J Antibiot (Tokyo) 1984;37:1449-1455.
26. Gras D, Bourdin A, Vachier I, de Senneville L, Bonnans C, Chanez P. An ex vivo model of severe asthma using reconstituted human bronchial epithelium. J Allergy Clin Immunol 2012;129:1259-1266.e1.
27. Korkmaz B, Attucci S, Juliano MA, Kalupov T, Jourdan ML, Juliano L, Gauthier F. Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates. Nat Protoc 2008;3:991-1000.
28. Wadhwa MS, Knoell DL, Young AP, Rice KG. Targeted gene delivery with a low molecular weight glycopeptide carrier. Bioconjug Chem 1995;6:283-291.
29. Shah PL, Scott SF, Knight RA, Hodson ME. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996;9:531-534.
30. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005;3:238-250.
31. Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010;1:440-464.
32. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100-109.
33. Beyerle A, Irmler M, Beckers J, Kissel T, Stoeger T. Toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications. Mol Pharm 2010;7:727-737.
34. Beyerle A, Merkel O, Stoeger T, Kissel T. PEGylation affects cytotoxicity and cell-compatibility of poly (ethylene imine) for lung application: structure-function relationships. Toxicol Appl Pharmacol 2010;242:146-154.
35. Hamano Y. Occurrence, biosynthesis, biodegradation, and industrial and medical applications of a naturally occurring e-poly-L-lysine. Biosci Biotechnol Biochem 2011;75:1226-1233.
36. Ko KH, Lee CJ, Shin CY, Jo M, Kim KC. Inhibition of mucin release from airway goblet cells by polycationic peptides. Am J Physiol 1999;277:L811-L815.
37. Duranton J, Boudier C, Belorgey D, Mellet P, Bieth JG. DNA strongly impairs the inhibition of cathepsin G by alpha (1)-antichymotrypsin and alpha (1)-proteinase inhibitor. J Biol Chem 2000;275:3787-3792.
38. Hilpert K, Elliott M, Jenssen H, Kindrachuk J, Fjell CD, Körner J, Winkler DF, Weaver LL, Henklein P, Ulrich AS, et al. Screening and characterization of surface-tethered cationic peptides for antimicrobial activity. Chem Biol 2009;16:58-69.